Eliem Therapeutics Inc
NASDAQ:ELYM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.45
10.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Eliem Therapeutics Inc
Eliem Therapeutics Inc
Other Long-Term Assets
Eliem Therapeutics Inc
Other Long-Term Assets Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eliem Therapeutics Inc
NASDAQ:ELYM
|
Other Long-Term Assets
$15k
|
CAGR 3-Years
-82%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$9.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
50%
|
CAGR 10-Years
28%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$4.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$8.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
37%
|
CAGR 10-Years
19%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3B
|
CAGR 3-Years
44%
|
CAGR 5-Years
15%
|
CAGR 10-Years
79%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$3.9B
|
CAGR 3-Years
66%
|
CAGR 5-Years
32%
|
CAGR 10-Years
30%
|
See Also
What is Eliem Therapeutics Inc's Other Long-Term Assets?
Other Long-Term Assets
15k
USD
Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Other Long-Term Assets amounts to 15k USD.
What is Eliem Therapeutics Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
-82%
Over the last year, the Other Long-Term Assets growth was -85%. The average annual Other Long-Term Assets growth rates for Eliem Therapeutics Inc have been -82% over the past three years .
You don't have any saved screeners yet
